There will be 2 sequential parts to the study:~Participants will be enrolled in Part A of the study first, which will only enroll those participants who are EBV-seropositive at Screening.~Part B will enroll only those participants who are EBV-seronegative at Screening.
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).